ArticlePakistan journal of medical sciences2025
Patatin-like phospholipase domain-containing 3 (PNPLA3) variants rs 738408 and rs 738409 single nucleotide polymorphism as predictor of metabolic associated fatty liver disease and its progression.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genome-wide association and polygenic risk score analyses of MASLD-related hepatic steatosis severity in a Taiwanese Han population.Cell & bioscience · 2026Article
- Integrated Genomic Analysis Reveals the Synergistic Role of PNPLA3 and ABCC8 Variants in Diabetic MASLD in Pakistan.Medical sciences (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To identify the PNPLA3 genetic variants as the potential predictors for metabolic associated fatty liver disease (MAFLD) and its progression among Pakistani population. Method: A cross sectional study comprising of 158 participants. They were included in this study with non-probability purposive sampling technique from Radiology Department of Aziz Fatimah Teaching Hospital and Aziz Fatimah Medical and Dental College, Pakistan. The duration of study was December 5, 2021 to April 4, 2024. Blood samples (10mL) were drawn for liver enzymes, gene analysis and ultimately PCR products were sent for Sanger sequencing. Data was analyzed using SPSS version 26 with p-Values ≤0.05 considered significant. Results: From 158 studied participants, 43.7% were male, and 56.3% were female. Of total population 51.3% were MAFLD positive while 48.7% were control subjects. Present results showed that CT and TT genotypes of rs738408 were frequently found in MAFLD group (p=0.039 and 0.060, respectively) and significant predictor for developing MAFLD (OR=2.484, p=0.019 and OR=5.167, p<0.001, respectively). Concerning progression of the disease CT genotype showed that subject with this genotype progress to moderate grade of fatty liver disease (OR=2.832, p=0.013). Whereas Odd ratio for TT genotype was significant for severe grade fatty liver diseases (OR=15.50, p=0.007). GG genotype of rs738409 was frequently found in MAFLD group (p=0.032). Odds ratio for GG genotype of rs738409 was significant for developing MAFLD (OR=4.565, p=0.025) and responsible to progress to moderate grade of fatty liver disease (OR= 5.083, p=0.022). Conclusion: CT and TT genotypes of 738408 and GG genotype of 738409 are associated with MAFLD and are at more risk for disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.